Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Substance P receptors and signal transduction in leukocytes.
Kavelaars A, Jeurissen F, Heijnen CJ. Kavelaars A, et al. Among authors: jeurissen f. Immunomethods. 1994 Aug;5(1):41-8. doi: 10.1006/immu.1994.1036. Immunomethods. 1994. PMID: 7531101
Activation of human monocytes via a non-neurokinin substance P receptor that is coupled to Gi protein, calcium, phospholipase D, MAP kinase, and IL-6 production.
Kavelaars A, Broeke D, Jeurissen F, Kardux J, Meijer A, Franklin R, Gelfand EW, Heijnen CJ. Kavelaars A, et al. Among authors: jeurissen f. J Immunol. 1994 Oct 15;153(8):3691-9. J Immunol. 1994. PMID: 7930588
Substance P induces a rise in intracellular calcium concentration in human T lymphocytes in vitro: evidence of a receptor-independent mechanism.
Kavelaars A, Jeurissen F, von Frijtag Drabbe Künzel J, Herman van Roijen J, Rijkers GT, Heijnen CJ. Kavelaars A, et al. Among authors: jeurissen f. J Neuroimmunol. 1993 Jan;42(1):61-70. doi: 10.1016/0165-5728(93)90213-i. J Neuroimmunol. 1993. PMID: 7678598
Monocytes express a non-neurokinin substance P receptor that is functionally coupled to MAP kinase.
Jeurissen F, Kavelaars A, Korstjens M, Broeke D, Franklin RA, Gelfand EW, Heijnen CJ. Jeurissen F, et al. J Immunol. 1994 Mar 15;152(6):2987-94. J Immunol. 1994. PMID: 7511635
Painful ophthalmoplegia from metastatic nonproducing parathyroid carcinoma: case study and review of the literature.
Eurelings M, Frijns CJ, Jeurissen FJ. Eurelings M, et al. Among authors: jeurissen fj. Neuro Oncol. 2002 Jan;4(1):44-8. doi: 10.1093/neuonc/4.1.44. Neuro Oncol. 2002. PMID: 11772432 Free PMC article. Review.
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM. Henricks LM, et al. Among authors: jeurissen fjf. Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348537
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Zwinkels H, Roon K, Jeurissen FJ, Taphoorn MJ, Hop WC, Vecht CJ. Zwinkels H, et al. Among authors: jeurissen fj. Oncol Nurs Forum. 2009 Mar;36(2):225-31. doi: 10.1188/09.ONF.225-231. Oncol Nurs Forum. 2009. PMID: 19273412
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM. Henricks LM, et al. Among authors: jeurissen fjf. Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11. Eur J Cancer. 2019. PMID: 30544060
PEG tube dependency after prophylactic placement in 209 head and neck cancer patients treated with chemoradiotherapy or radiation with cetuximab.
Vrolijk LB, de Roij van Zuijdewijn CLM, Slingerland M, Wiggenraad RGJ, Verschuur HP, Jeurissen FJF. Vrolijk LB, et al. Among authors: jeurissen fjf. Clin Otolaryngol. 2019 Mar;44(2):172-175. doi: 10.1111/coa.13282. Epub 2019 Feb 4. Clin Otolaryngol. 2019. PMID: 30615256 No abstract available.
Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
Ham JC, van Meerten E, Fiets WE, Beerepoot LV, Jeurissen FJF, Slingerland M, Jonker MA, Husson O, van der Graaf WTA, van Herpen CML. Ham JC, et al. Among authors: jeurissen fjf. Head Neck. 2020 May;42(5):828-838. doi: 10.1002/hed.26053. Epub 2020 Jan 6. Head Neck. 2020. PMID: 31903657 Free PMC article.
26 results
Jump to page
Feedback